This content is from: Portfolio Hedge Fund Manager Kyle Bass Declares War on Drug Prices Through his Coalition for Affordable Drugs, Bass is challenging pharmaceuticals companies’ patents and shorting their stocks. By Jess Delaney October 22, 2015
This content is from: Portfolio Drug Wars: The Battle to Put a Lid on Rising Prices In the first of five stories on the battle to address skyrocketing drug prices in the U.S., Institutional Investor looks at how the actions of Turing Pharmaceuticals CEO Martin Shkreli set off a firestorm in Washington. By Khadijah M. Silver November 25, 2015
Get smart Texas Pacific Group's stake in French smart-card maker Gemplus has become a cause célèbre in Paris amid charges of a CIA role. The Americans' only real plot: to make some profits. April 11, 2004
This content is from: Research The best of the BUY SIDE 2002 The bear market has emboldened competitors and frayed client relationships. Meet 25 equity analysts at major European asset managers who are rising to the new challenges. By Paul Crowney April 30, 2002
